Senti Biosciences Inc
For the period ended Mar 31, 2024. Filed May 9, 2024.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2024 · Filed May 9, 2024
SNTI$0.14-11.5%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Balance Sheets
(in thousands, except share and per share data)
| March 31, | December 31, | |
|---|---|---|
| 2024 | 2023 | |
| Assets | ||
| Cash and cash equivalents | $23,723 | $35,926 |
| Accounts receivable | 76 | 112 |
| GeneFab receivable - related party | 17,847 | 17,592 |
| GeneFab prepaid expenses - related party | 11,300 | 14,787 |
| Prepaid expenses and other current assets | 2,720 | 2,783 |
| Total current assets | 55,666 | 71,200 |
| Restricted cash | 4,028 | 3,522 |
| GeneFab receivable - related party, net of current portion | 383 | 1,119 |
| Property and equipment, net | 24,354 | 25,338 |
| Operating lease right-of-use assets | 15,797 | 16,274 |
| GeneFab Economic Share - related party | 1,871 | 1,816 |
| Other long-term assets | 86 | 215 |
| Total assets | $102,185 | $119,484 |
| Liabilities and Stockholders’ Equity | ||
| Accounts payable | $1,624 | $1,250 |
| Finance lease liabilities - related party, current portion | 100 | 97 |
| Early exercise liability, current portion | 111 | 135 |
| GeneFab sublease deferred income - related party | 862 | 989 |
| Accrued expenses and other current liabilities | 2,734 | 5,927 |
| Operating lease liabilities | 4,178 | 4,031 |
| Current liabilities of discontinued operations | — | 243 |
| Total current liabilities | 9,609 | 12,672 |
| Operating lease liabilities, net of current portion | 32,445 | 33,538 |
| Contingent earnout liability | 20 | 20 |
| GeneFab Option - related party | 4,017 | 6,331 |
| Early exercise liability, net of current portion | — | 10 |
| Total liabilities | 46,091 | 52,571 |
| Commitments and contingencies (Note 12) | ||
| Stockholders’ equity: | ||
| Preferred stock, $0.0001 par value; 10,000,000 shares authorized at March 31, 2024 and December 31, 2023; zero shares issued and outstanding at March 31, 2024 and December 31, 2023, respectively | — | — |
| Common stock, $0.0001 par value; 500,000,000 shares authorized at March 31, 2024 and December 31, 2023; 45,712,821 and 45,700,161 shares issued and outstanding at March 31, 2024 and December 31, 2023, respectively | 5 | 5 |
| Additional paid-in capital | 312,544 | 311,252 |
| Accumulated other comprehensive income | — | — |
| Accumulated deficit | (256,455) | (244,344) |
| Total stockholders’ equity | 56,094 | 66,913 |
| Total liabilities and stockholders’ equity | $102,185 | $119,484 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.